Stocks:
5,169
ETFs:
2,288
Exchanges:
11
Market Cap:
$65.09T
24h Vol:
$8.59B
Dominance:
MSFT:4.90%
Stocklytics Platform
Asset logo for symbol RSLS
ReShape Lifesciences
RSLS
59
$0.19arrow_drop_down3.92%-$0.00
Penny Stock

Performance History

Chart placeholder
Key Stats
Open$0.19
Prev. Close$0.20
EPS-0.44
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap5714149.00
PE Ratio-
LOWHIGH
Day Range0.19
0.21
52 Week Range0.14
2.44
Ratios
P/B Ratio0.58
Revenue-
Operating M. %-113.68%
Earnings$0.00
Earnings Growth %75.36%
EBITDA Margin %-127.98%
ROE %-177.64%
EPS-0.44

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

info
There's no data available for Analyst Forecast

Analyst Ratings

info
There's no data available for Analyst Ratings

Correlated Companies

PRICE$878.45
24H (%)arrow_drop_down0.55%
24H ($)-$4.88
MARKET CAP$771.28B
PRICE$497.12
24H (%)arrow_drop_down0.03%
24H ($)-$0.17
MARKET CAP$443.63B
PRICE$145.53
24H (%)arrow_drop_up0.06%
24H ($)$0.09
MARKET CAP$347.62B
PRICE$129.48
24H (%)arrow_drop_up0.08%
24H ($)$0.11
MARKET CAP$318.88B

About ReShape Lifesciences (RSLS)

ReShape Lifesciences Inc., a medical device company, provides products and services that manages and treat obesity and metabolic diseases in the United States, Australia, Europe, and internationally. The company's product portfolio includes Lap-Band System, a minimally invasive long-term treatment of severe obesity and more invasive surgical stapling procedures, such as the gastric bypass or sleeve gastrectomy and ReShape Vest system, a laparoscopically implantable device to enable weight loss and stomach preservation. It also offers ReShapeCare virtual health coaching program, a program that supports healthy lifestyle changes for all medically managed weight-loss patients; and ReShape Diabetes Bloc-Stim Neuromodulation, a technology that is in preclinical development for the treatment of type 2 diabetes mellitus. In addition, the company provides Obalon Balloon System, a swallowable capsule used to track and display the location of the balloon during placement. The company was formerly known as EnteroMedics Inc. and changed its name to ReShape Lifesciences Inc. in 2017. ReShape Lifesciences Inc. was incorporated in 2002 and is headquartered in San Clemente, California.

Sector
Healthcare
Industry
Medical Devices
CEO
Mr. Paul F. Hickey
Headquarters
San Clemente
Employees
40
Exchange
NASDAQ
add ReShape Lifesciences to watchlist

Keep an eye on ReShape Lifesciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is ReShape Lifesciences's (RSLS) price per share?

The current price per share for ReShape Lifesciences (RSLS) is $0.2. The stock has seen a price change of -$0.01 recently, indicating a -3.92% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for ReShape Lifesciences (RSLS)?

For ReShape Lifesciences (RSLS), the 52-week high is $2.45, which is 1.15K% from the current price. The 52-week low is $0.14, the current price is 39.01% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is ReShape Lifesciences (RSLS) a growth stock?

ReShape Lifesciences (RSLS) has shown an average price growth of 0.41% over the past three years. It has received a score of -7 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ReShape Lifesciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is ReShape Lifesciences (RSLS) stock price performance year to date (YTD)?

As of the latest data, ReShape Lifesciences (RSLS) has a year-to-date price change of -26.54%. Over the past month, the stock has experienced a price change of 12.64%. Over the last three months, the change has been 20.62%. Over the past six months, the figure is -40.79%.

help
Is ReShape Lifesciences (RSLS) a profitable company?

ReShape Lifesciences (RSLS) has a net income of -$11.39M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 63.93% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -113.68% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. The gross profit is $5.55M. Operating income is noted at -$14.64M. Furthermore, the EBITDA is -$11.11M.

help
What is the market capitalization of ReShape Lifesciences (RSLS)?

ReShape Lifesciences (RSLS) has a market capitalization of $5.71M. The average daily trading volume is 1.47M, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Take Your Investments to a Whole New Level